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Background: S1400D is a biomarker-driven therapeutic
substudy of Lung-MAP evaluating the ﬁbroblast growth
factor (FGF) receptor (FGFR) inhibitor AZD4547 in patients
with FGF pathway-activated squamous cell. This is the ﬁrst
phase II trial to evaluate AZD4547 as a targeted approach in
patients with previously treated FGFR-altered squamous
cell NSCLC and is the ﬁrst demonstration of successful
implementation and conduct of a national umbrella protocol
in this disease setting.
Methods: Eligible patients had tumoral FGFR alteration or
mutation and had progressive disease after at least one line
of platinum-based systemic therapy. Patients received
AZD4547 80 mg twice daily orally. Primary endpoint was
response by Response Evaluation Criteria in Solid Tumors
version 1.1; secondary endpoints included progression-free
survival, overall survival, and duration of response (DoR).
Results: Ninety-two patients were assigned to S1400D,
43 were enrolled, and 27 AZD4547-treated patients were
evaluable. Evaluable patients were predominantly white
(n ¼ 24, 89%), median age 66 years (range, 49–88 years
old), and female (n ¼ 7, 26%). FGFR alterations included
FGFR1 ampliﬁcation (n ¼ 23; 85%), FGFR3 ampliﬁcation
(n ¼ 2; 7%), FGFR3 S249C (n ¼ 2; 7%), and FGFR3 fusion
(n ¼ 1; 4%). Treatment with ADZ4547 was well tolerated;
grade 3 adverse events occurred in six patients, and one
patient had grade 4 sepsis. Of 27 response-evaluable
patients, 1 patient with FGFR3 S249C had unconﬁrmed
partial response with a DoR of 1.5 months and 1 patient
with FGFR1 ampliﬁcation had a conﬁrmed partial response
with a DoR of 2.9 months (7%, 95% conﬁdence interval
[CI]: 0%–17%). Median progression-free survival and
overall survival for the AZD4547-treated cohort were 2.7
months (95% CI: 1.4– 4.5 months) and 7.5 months (95% CI:
3.7–9.3 months).
Conclusions: AZD4547 had an acceptable safety proﬁle but
minimal activity in this predominantly FGFR1/FGFR3–
ampliﬁed cohort. Evaluation of other targeted agents in
Lung-MAP is ongoing.
 2019 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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Squamous cell NSCLC (SqNSCLC) comprises approx-
imately 20% to 30% of all cases of NSCLC.1 In contrast to
the therapeutic advances seen in nonsquamous NSCLC,
including molecular characterization and use of targeted
therapy for relevant actionable oncogenic driver muta-
tions (e.g., EGFR, ALK receptor tyrosine kinase [ALK]),
there has been limited progress in the personalizedmedicine approaches for SqNSCLC.2 Platinum-based
combination therapy currently remains the backbone
of ﬁrst-line systemic palliative therapy for advanced
SqNSCLC, with modest improvement in outcomes seen
with the addition of agents such as the EGFR monoclonal
antibody necitumumab, vascular endothelial growth
factor targeting with ramucirumab, and afatinib in
molecularly unselected patients. In the second-line
setting, the paradigm of therapy for SqNSCLC has
changed signiﬁcantly with the approval of immune
checkpoint inhibitors.
Molecular genotyping has led to the potential appli-
cation of targeted agents for prevalent mutations in
SqNSCLC. The Lung Master Protocol (Lung-MAP, SWOG
S1400) is an umbrella protocol which contains a next-
generation sequencing (NGS) screening component and
multiple independently conducted and analyzed treat-
ment substudies.3 The overarching goal of the umbrella
master protocol is to genomically screen a large popu-
lation of previously treated SqNSCLC patients to evaluate
targeted therapies (or combinations) in biomarker-
driven substudies and immunotherapy combinations
that can lead to approval of efﬁcacious regimens. Here
we report on results of SWOG S1400D, a phase II
biomarker-driven therapeutic substudy of Lung-MAP
evaluating the ﬁbroblast growth factor receptor (FGFR)
inhibitor AZD4547 in patients with FGFR pathway–
activated SqNSCLC after failure of platinum-based
therapy.4 Ampliﬁcations of FGFR1 have been described
in up to 20% of SqNSCLC cases with mutations and
fusions in FGFR2 and FGFR3 occurring at a lower
incidence (each less than 4%).
In preclinical studies, AZD4547 is active against
tumor cell lines and tumors bearing a broad range of
FGFR ampliﬁcations/mutations, and AZD4547 induces
tumor regression or stasis in patient-derived explant
xenograft models carrying FGFR1 gene ampliﬁcation.4,5
In a small clinical study in SqNSCLC there was at least
one partial response (PR) among the 14 patients
treated with AZD4547, and that patient carried FGFR1
ampliﬁcation.6 These preclinical and early clinical data
coupled with the lack of signiﬁcant long-term safety
concerns for the drug administered as monotherapy
led to the development of S1400D using AZD4547
as potential targeted therapy for FGFR-positive
SqNSCLC.Patients and Methods
Patients with previously treated and histologically
proven SqNSCLC were eligible for the Lung-MAP pro-
tocols’ previously described eligibility criteria.3 Substudy
eligibility was determined based on an NGS-based
mutational analysis of the patient’s tumor. Mutational
Table 2. Gene Alterations Detected on FMI NGS Screening
(n ¼ 27)a
n (%)
Study eligibility alterations (FGFRþ)
FGFR1 ampliﬁcation 23 (85)
FGFR3 S249C 2 (7)
FGFR3 ampliﬁcation 2 (7)
FGFR3 fusion 1 (4)
Number of FGFR gene alterations
1 26 (96)
2 1 (4)
TMB score (n ¼ 25)b
Median 10.88
Range 2.42-21.77
Interquartile range 8.46-15.72
<10 12 (48)
10 13 (52)
Other concomitant gene alterations
Short variants
TP53 26 (96)
MLL2 5 (19)
CDKN2A, NF1, NFE2L2 3 (11)
FBXW7, LRP1B, PAX5, SMAD4 2 (7)
BRCA2, CREBBP, DAXX, EP300, GATA2, HRAS, 1 (4)
--- 2019 LUNG-MAP S1400D: Phase II Study of FGFR Inhibitor 3analysis, including determination of tumor mutational
burden (TMB), was performed on archival formalin-ﬁxed
parafﬁn-embedded tumor specimens using Foundatio-
nOne (Foundation Medicine, Cambridge, Massachusetts).
The full list of alterations evaluated is included in
Supplementary Table 1. The FGFR alterations required
for eligibility to S1400D were FGFR1/FGFR2/FGFR3
ampliﬁcations, fusions, or substitutions. Ampliﬁcation
was deﬁned as greater than or equal to six estimated
copies (or greater than or equal to seven for triploid or
greater than or equal to eight for tetraploid samples).
In addition, eligibility to S1400D included age greater
than or equal to 25 years; Zubrod performance score of
0-2; measurable disease by Response Evaluation Criteria
in Solid Tumors version 1.1; adequate hematologic,
hepatic, cardiac, renal, and ophthalmologic function; and
no impairment of gastrointestinal function or gastroin-
testinal disease that could signiﬁcantly alter absorption
of AZD4547. Exclusion criteria included leptomeningeal
disease; symptomatic, untreated brain metastases; and
chemotherapy within 21 days before registration.
Written informed consent was required from all patients
before enrollment in the master protocol and a separate
consent form was required for treatment on the speciﬁc
substudy.
AZD4547 was administered orally at 80 mg twice
daily. Treatment cycles were 21 days. Fasting was not
required; however, AZD4547 was not administered with
foods known to modulate CYP3A4 or CYP2D6 enzyme
activity. Disease assessment occurred every two cycles,
and treatment could continue until progression. Dose
reductions and adjustments were discussed with theTable 1. Patient Demographics and Characteristics (n ¼ 27)
Characteristics n (%)
Age, median (range), years 66.3 (49-88)
Male 20 (74)
Performance Status
0 4 (15)
1 23 (85)
2 0 (0)
Race/ethnicity
White 24 (89)
Black 3 (11)
Asian 0 (0)
Hispanic 2 (7)
Number of prior lines of therapy for
stage IV disease
0 2 (7)
1 22 (82)
2 or more 3 (11)
Smoking status
Current smoker 11 (41)
Former smoker 16 (59)
Never smoker 0 (0)study chair and were followed as speciﬁed in the
protocol.Statistical Considerations
The primary objective for S1400D was to evaluate the
response rate (RR) (conﬁrmed and unconﬁrmed, com-
plete, and partial) in patients treated with AZD4547. TheKDM6A, MYD88, NOTCH1, PALB2, PIK3R1,
PTCH1, PTEN, RB1, RNF43, STAG2, TSC1
Copy number alterations
ZNF703 18 (67)
MYST3 10 (37)
SOX2 9 (33)
PIK3CA, RICTOR 6 (22)
MYC 5 (19)
CDKN2A, CDKN2B 4 (15)
AKT2, FGF10 3 (11)
CTNNB1, FGF12, GNAS, IRS2, KDM5A, KDM6A,
NF1, PTEN
2 (7)
AKT1, ARFRP1, ARID1A, AURKA, AXL, BAP1,
BCL2L2, CCND1, CDK8, ERBB2, ERBB3,
FGF19, FGF3, FGF4, FLT3, JUN, KDR, KIT,
KRAS, MCL1, MTOR, NFKBIA, NKX2-1, NRAS,
PDGFRA, PRSS8, RB1, RPTOR, SRC, TSC1,
ZNF217
1 (4)
Rearrangements
LRP1B 2 (7)
ARID1A, BRCA2, CDKN2A, PRDM1, PTEN, ROS1 1 (4)
aFull list of alterations is included in Supplementary Table 1.
bTMB was calculated as the number of somatic, coding, short variants,
excluding known driver mutations, per megabase of the genome interro-
gated; TMB score was not evaluable for two patients.
FMI, Foundation medicine; NGS, next-generation sequencing; FGFR, ﬁbro-
blast growth factor receptor; TMB, tumor mutational burden.
Table 3. Adverse Events Attributed to Treatment (n ¼ 27)
AE
Grade
3 4 5
Dyspnea 1 (4)
Fatigue 1 (4)
Hyponatremia 1 (4)
Lung infection 1 (4)
Lymphocyte count decreased 1 (4)
Mucositis oral 1 (4)
Retinopathy 1 (4)
Sepsis 1 (4)
Maximum grade of any AE 6 (22) 1 (4) 0
Values shown are n (%).
AE, adverse event.
4 Aggarwal et al Journal of Thoracic Oncology Vol. - No. -sample size (n ¼ 40) was based on a design with 91%
power to rule out a RR of 15% at the one-sided 5% level
if the true rate was 35%. A key secondary objective was
an investigator assessment of median progression-freeFigure 1. Waterfall plot of response to AZD4547. Each vertic
burden when compared to baseline as deﬁned by RECIST 1.1. On
in the plot. Patients who did not have follow up tumor disease a
with IA. Patients who had new lesions appear at their ﬁrst follo
target lesions and marked with NL. Patients who had unequivo
assessment were presented with percentage change in target l
ﬁrst scheduled disease assessment and the death can reasonab
sented graphically as a 100% increase in tumor burden. Pa
assessment were marked as SD. Patients who expired prior to di
marked as ED. Negative numbers represent decrease in tumor
crease in tumor burden from baseline. cFGFR, ﬁbroblast growtsurvival (mPFS). If the RR was less than 25% but the
mPFS was at least 4.5 months, this would be considered
sufﬁcient evidence to continue to phase III. With 40
patients, this design had 90% power to rule out an mPFS
of 3 months or less if the true mPFS was 6 months at the
5% one-sided level. Binary proportions and associated
95% conﬁdence intervals (CIs) were estimated. Survival
distributions were estimated using the Kaplan-Meier
method and the Brookmeyer-Crowley method was
used to estimate CIs.Results
Baseline patient characteristics for the 27 evaluable
patients are displayed in Table 1. Frequency of FGFR
alterations among evaluable patients were as follows:
FGFR1 ampliﬁcation (n ¼ 23, 85%); FGFR3 ampliﬁcation
(n ¼ 2, 7%); FGFR3 S249C (n ¼ 2, 7%); and FGFR3
fusion (n ¼ 1, 4%) (Table 2). All but one patient had one
FGFR alteration detected; one patient had two FGFRal bar represents a patient’s best percent change in tumor
ly patients with measurable disease at baseline are presented
ssessment were presented at the very left of the plot marked
w-up assessment were presented with percentage change in
cal progression in non-target lesions at their ﬁrst follow-up
esions and marked with UP. Patients who expired prior to the
ly be assumed to be due to disease progression were repre-
tients who had symptomatic deterioration at ﬁrst disease
sease assessment, but the death was not due to disease were
burden from baseline while positive numbers represent in-
h factor receptor.
Figure 2. Kaplan-Meier curves of progression-free survival
(PFS) and overall survival (OS). (A) PFS. (B) OS. Conf. int.,
conﬁdence interval.
--- 2019 LUNG-MAP S1400D: Phase II Study of FGFR Inhibitor 5alterations. The median and range TMB scores were
10.88 (range: 2.42–21.77), with 13 (52%) patients
having TMB scores greater than or equal to 10.
Overall, treatment with AZD4547 was well tolerated
(Table 3). Treatment-related grade 3 adverse events
(AEs) were seen in six patients. One patient had grade 4
sepsis possibly related to study drug. There were no
grade 5 AEs. Patients received a median of two cycles
(range: 1–12, interquartile range: 2–3) of AZD4547.
Of 27 response-evaluable patients, 2 patients had PR
(7%, 95% CI: 0%–17%): 1 with FGFR3 S249C gene
mutation and 1with FGFR1 ampliﬁcation, with a duration of
response of 1.5 months and 2.9 months, respectively. The
magnitude of response for the 27 evaluable patients by
submutation is depicted in the waterfall plot in Figure 1.
mPFS was 2.7 months (95% CI: 1.4–4.5 months). Median
overall survival (OS) was 7.5 months (95% CI: 3.7–9.3
months) (Fig. 2). The 1- and 2-year OS estimates were
25.9% and 7.4%, respectively. Forest plot analyses for
PFS and OS showed a signiﬁcantly worse OS (but not
PFS) for current versus former smokers (there were no
never-smokers in this study) (Supplementary Fig. 1).
Current smokers had a four-fold increased risk of deathover former smokers (hazard ratio ¼ 4.12; 95% CI:
1.53–11.10; p ¼ 0.005). However, no subgroup derived
signiﬁcant beneﬁt from treatment with AZD4547.
Discussion
Unfortunately, despite early promise, AZD4547 showed
minimal antitumor activity in this previously treated,
genomically selected SqNSCLC patient population with
FGFR pathway activation. In this cohort, FGFR1 ampliﬁca-
tion was the most common alteration followed by FGFR3
ampliﬁcation. Two patients had short-lived PRs, one of
which was seen in a patient with FGFR3 S249 C gene mu-
tation, and the other one in a patient with FGFR1 ampliﬁ-
cation, consistent with previous reports of activity of this
drug in an ampliﬁed tumor. Very few patients had FGFR
mutations or fusions; therefore, conclusions regarding ef-
ﬁcacy in this subpopulation should await further investi-
gation. AZD4547 was overall well tolerated, and no
signiﬁcant safety signals were noted.
We believe there are several reasons why this trial was
not successful. First, the biology of SqNSCLC remains com-
plex. Unlike oncogene-addicted adenocarcinomas, such as
EGFRmutant, orALK rearrangedNSCLC, squamous cell lung
cancers often have multiple mutations without a single
driver mutation. They are characterized by a high overall
mutational burden, at a rate of 8.1 mutations per megabase.
Almost all patients display somatic mutations of tumor
protein p53 (TP53), and the most commonly observed al-
terations are in pathways associated with tumor growth,
proliferation, and survival. Because the growth and
signaling pathways are complex, we hypothesize that one
drugmaynot be adequate to effectively inhibit the growth of
the FGFR-altered tumors studied in this trial. Additionally,
FGFR ampliﬁcations are biologically different from FGFR
fusions or mutations in that they represent a potentially
heterogeneous aberration, with different response to tar-
geted therapies and potentially different resistance mecha-
nisms. It is entirely possible that aswe target the initial FGFR
ampliﬁcation there may be complex resistance pathways in
place to enable tumor growth and survival. It is also possible
that AZD4547 was just not effective; however, selection of
the drug was based on preclinical activity and evidence of
clinical activity in a phase I study.
Although this was a negative study, there are several
positive takeaways. The Lung-MAP study was broadly
designed to include patients with previously treated
squamous cell carcinoma. The protocol was swiftly amen-
ded to alter randomization when standard-of-care was
changed, and multiple substudies such as S1400D were
designed that could open and close autonomously and
allow for rapid identiﬁcation and evaluation of targeted
agents. Each substudy was then redesigned as a phase II
study, and futility analyses were built in to enable early
termination as in this study. Importantly, S1400D
6 Aggarwal et al Journal of Thoracic Oncology Vol. - No. -represents a successful and extensive collaboration be-
tween industry, academia, and national organizations such
as the Foundation for the National Institutes of Health and
the National Cancer Institute, and evaluation of other tar-
geted agents in Lung-MAP is ongoing.
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